> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# uniQure Seeks FDA Approval for Huntington’s Gene Therapy
- URL: https://www.theamericanquorum.com/uniqure-seeks-fda-approval-for-huntingtons-gene-therapy/
- Published: 2026-09-03T10:59:15.000Z
- Updated: 2026-09-03T10:59:15.000Z
- Description: uniQure has asked U.S. regulators to accelerate approval of AMT-130, a one-time gene therapy for Huntington’s disease. The filing rests on promising but externally controlled Phase I/II evidence.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare

uniQure submitted AMT-130, its experimental one-time gene therapy for Huntington’s disease, for approval in the United States and the United Kingdom on September 2\. The company asked the Food and Drug Administration to use accelerated approval and grant priority review, while the British filing seeks a standard marketing authorization. The simultaneous applications move the program from an early clinical experiment into its most consequential regulatory test, according to the company’s [filing announcement](https://uniqure.gcs-web.com/node/12991/pdf?ref=theamericanquorum.com).

The application rests on a striking but complicated result. Among 12 patients who received the high dose, uniQure said decline on the composite Unified Huntington’s Disease Rating Scale was 75% slower over 36 months than in a matched group drawn from a natural-history database. That comparison produced a statistically significant result, but it was not a concurrent randomized efficacy comparison. [Reuters](https://www.reuters.com/legal/litigation/uniqure-seeks-us-approval-huntingtons-gene-therapy-after-fda-reversal-2026-09-02/?ref=theamericanquorum.com) reported that this design question sat at the center of months of disagreement between the company and the FDA.

The stakes are high because Huntington’s is progressive, inherited and ultimately fatal, while available medicines address symptoms rather than the underlying disease. uniQure estimates that about 75,000 people live with Huntington’s across the United States, European Union and United Kingdom, with many more carrying the mutation that can cause it. Its formal [SEC notice](https://www.sec.gov/Archives/edgar/data/1590560/000110465926104463/qure-20260902x8k.htm?ref=theamericanquorum.com) confirms that both applications were submitted, but submission is not approval and does not ensure either regulator will accept the dossiers for full review.

## A One-Time Treatment Delivered to the Brain

AMT-130, also called ifezuntirgene inilparvovec, uses an adeno-associated virus vector to deliver an engineered microRNA intended to reduce production of huntingtin protein. The therapy is administered once through MRI-guided, convection-enhanced infusion into the caudate and putamen, structures within the striatum that are heavily affected by Huntington’s. The approach is designed to produce sustained gene silencing inside brain cells, rather than requiring repeated systemic dosing, as the company’s [program summary](https://www.uniqure.com/programs-pipeline/huntingtons-disease?ref=theamericanquorum.com) explains.

That delivery method also raises the practical threshold for use. Patients undergo stereotactic neurosurgery at a center equipped for image-guided infusion, and the viral vector cannot simply be withdrawn after administration. Regulators therefore must weigh more than whether a score changed: they must assess manufacturing consistency, surgical reproducibility, neurological safety and whether expected benefit justifies an irreversible intervention.

The proposed population consists of adults with early manifest Huntington’s disease, when measurable symptoms have appeared but substantial function remains. Treating earlier may preserve more neurological capacity, yet it also exposes people who can still work and live independently to a demanding procedure whose very long-term effects remain uncertain. That balance is why durable follow-up matters especially for a gene therapy intended to remain active for years rather than a drug that can be stopped when problems arise.

## What the 36-Month Evidence Shows

The core U.S. trial began with 26 participants: six assigned to a low dose, 10 to a high dose and 10 to an imitation-surgery control. Four people in the control arm later crossed over to treatment after roughly 12 months. A separate European study enrolled 13 treated patients, while additional cohorts examined immune suppression and people with smaller striatal volumes. The public [trial record](https://clinicaltrials.gov/study/NCT04120493?ref=theamericanquorum.com) shows the program was primarily designed to evaluate safety, tolerability and early biological or clinical signals.

For its pivotal analysis, uniQure compared treated participants with similar patients from Enroll-HD, a large observational study of Huntington’s progression. The high-dose group declined by an average 0.38 points on the composite scale over 36 months, versus 1.52 points in the external control, a difference the company translated into 75% slower progression. Its [topline results](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii?ref=theamericanquorum.com) also reported supportive trends on motor and functional measures, though these remain company-sponsored findings from a small cohort.

Propensity-score matching can balance observed characteristics such as age, disease stage and baseline performance. It cannot guarantee balance in unmeasured factors, differences in assessment or changes in care between a trial and an observational database. Nor can a 12-person high-dose cohort reveal uncommon adverse effects reliably. An independent [clinical commentary](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2825%2900546-2/fulltext?ref=theamericanquorum.com) described the result as promising while emphasizing that external controls and small samples limit certainty about the magnitude of benefit.

The original sham group still contributes useful evidence about procedure safety and short-term measurement, but its later crossover means it cannot provide a three-year randomized comparison. This is not a technical footnote: Huntington’s progression varies among individuals, and composite scales combine motor function, cognition and daily capability. A large apparent difference can be clinically important while still carrying more uncertainty than the same difference observed in a conventional, adequately powered randomized trial.

## Why the FDA Changed Course

The filing follows an unusually public regulatory reversal. In November 2025, uniQure said the FDA no longer considered the existing clinical package adequate as primary evidence for a biologics application, contradicting the company’s understanding of earlier discussions. Shares fell 58% after that disclosure, [Reuters reported](https://www.reuters.com/business/healthcare-pharmaceuticals/fda-says-clinical-data-uniqures-huntingtons-disease-therapy-not-adequate-2025-11-03/?ref=theamericanquorum.com). The agency’s concern centered on whether the externally controlled analysis could establish effectiveness without another study using a concurrent control.

After a January Type A meeting, formal minutes received in March still said the external-control data were insufficient at that time. In June, the company said the FDA had agreed that the 36-month analysis could support an accelerated-approval submission. That agreement permitted uniQure to file; it did not predetermine acceptance, priority review or approval. The FDA has not publicly released a detailed account explaining how its evidentiary assessment changed or what commitments may be required.

The dispute reflects a genuine trade-off. A new sham-controlled neurosurgical trial could give a cleaner efficacy estimate, but it would ask participants to undergo an invasive imitation procedure and delay access to treatment in a relentlessly progressive disease. External controls avoid that burden and can shorten development, yet they transfer more weight to statistical assumptions. Regulators must decide whether the total evidence is persuasive enough for earlier access and whether remaining uncertainty can be managed after approval.

## Accelerated Approval Preserves Uncertainty

The FDA’s [accelerated pathway](https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program?ref=theamericanquorum.com) allows earlier approval for serious diseases with unmet need based on an endpoint reasonably likely to predict benefit or, in some cases, an intermediate clinical endpoint. Sponsors must generally verify the anticipated benefit after approval, and the agency can move to withdraw a therapy if required evidence fails. uniQure has not disclosed every detail of the proposed regulatory basis, and the FDA has not accepted the application publicly.

Before substantive review, the agency normally spends about 60 days determining whether a filing is complete enough to receive. If it accepts the application and grants priority review, uniQure expects a six-month review clock rather than the standard 10 months. Those periods begin after filing review, so they should not be read as an approval date. Requests for priority treatment can be denied, reviews can be extended and regulators can demand additional analyses, manufacturing information or clinical evidence.

The British application creates a parallel evaluation by the Medicines and Healthcare products Regulatory Agency. A second regulator examining the same package may provide an important comparison because standards and procedural routes differ, even when the underlying evidence does not. Separate submissions also do not imply synchronized decisions. Either authority could seek different follow-up, labeling or risk controls, and neither application yet answers questions about pricing, coverage or the number of centers able to deliver treatment.

## The Next Data Will Shape the Decision

uniQure expects to report four-year follow-up before the end of the third quarter. That update should show whether the separation from external controls persists, narrows or grows, and whether any delayed safety signals emerge. Durability is central to the treatment’s value: a one-time intervention becomes more compelling if its clinical effect lasts, but a fading benefit or late toxicity would be harder to manage after irreversible delivery. Longer observation still cannot remove every limitation of the nonconcurrent comparison.

If accelerated approval is granted, the design and timing of confirmatory research will be as important as the initial decision. FDA [guidance](https://www.fda.gov/media/184120/download?ref=theamericanquorum.com) says confirmatory trials should generally be underway promptly and directly verify clinical benefit. For AMT-130, regulators will need a plan that is scientifically credible and ethically workable once patients can obtain an approved therapy. Clear milestones would help prevent provisional evidence from becoming the permanent evidence base.

For families facing Huntington’s, the submission is meaningful because it brings the first potentially disease-modifying gene therapy to regulators on both sides of the Atlantic. It is not yet proof that AMT-130 works, nor a signal for patients to seek treatment outside research. The coming reviews must determine whether a large slowing signal from a small externally controlled cohort is reliable enough to justify access now—and what evidence must follow if the answer is yes.